Japan Contract Development Manufacturing Organization Market Size, Share & Trends Analysis Report By Product Type (API, Drug Product), By Workflow (Clinical, Commercial), By Application (Oncology, Hormonal, Glaucoma), By Country, And Segment Forecasts, 2024 - 2030
This report can be delivered to the clients within Immediate
Japan CDMO Market Growth & Trends
The Japan CDMO market is expected to reach USD 19.49 billion by 2030 and is projected to register a CAGR of 6.8% from 2024 to 2030, according to a new report by Grand View Research, Inc. The increasing demand for biopharmaceuticals, a high burden of diseases, and the rising geriatric population are some of the key growth drivers. Growing investments by various Contract Development and Manufacturing Organizations (CDMOs) for facility and service expansion are likely to boost the market over the forecast period.
In addition, increasing pharmaceutical R&D investments are driving the market growth. As pharmaceutical companies invest more in R&D, they may seek external expertise and resources to accelerate drug development processes. CDMOs provide specialized services in drug development, manufacturing, and testing, making them valuable partners for pharmaceutical companies looking to outsource certain aspects of their R&D activities. Several players are investing in the R&D activities of pharmaceuticals. For instance, in March 2022, WuXi AppTec launched Tetracycline-Enabled Self-Silencing Adenovirus (TESSA) technology to accelerate the production of adeno-associated viruses for drugs in cell and gene therapy.
The increase in outsourcing services by pharmaceutical companies in the pharmaceutical industry has profoundly impacted the Japan market.The trend of outsourcing activities in the pharmaceutical domain is rising as companies find value in acquiring additional competencies essential for successful drug development & commercialization. Besides providing extended expertise & assisting in improved cash flow management, outsourcing brings significant manufacturing advantages, including reducing investment risks.
Notably, regulatory authorities in Japan have accelerated approval for regenerative medical and gene therapy products. For instance, the adoption of the Pharmaceuticals and Medical Devices Act (PMD Act), 21st Century Cures Act, and PRIME (Priority Medicines) Initiative has helped the country improve access to regenerative medicines. Such initiatives by regulatory agencies are expected to improve the demand for the development and manufacturing of regenerative medicines in the country.
Japan CDMO Market Report Highlights
Japan CDMO Market Growth & Trends
The Japan CDMO market is expected to reach USD 19.49 billion by 2030 and is projected to register a CAGR of 6.8% from 2024 to 2030, according to a new report by Grand View Research, Inc. The increasing demand for biopharmaceuticals, a high burden of diseases, and the rising geriatric population are some of the key growth drivers. Growing investments by various Contract Development and Manufacturing Organizations (CDMOs) for facility and service expansion are likely to boost the market over the forecast period.
In addition, increasing pharmaceutical R&D investments are driving the market growth. As pharmaceutical companies invest more in R&D, they may seek external expertise and resources to accelerate drug development processes. CDMOs provide specialized services in drug development, manufacturing, and testing, making them valuable partners for pharmaceutical companies looking to outsource certain aspects of their R&D activities. Several players are investing in the R&D activities of pharmaceuticals. For instance, in March 2022, WuXi AppTec launched Tetracycline-Enabled Self-Silencing Adenovirus (TESSA) technology to accelerate the production of adeno-associated viruses for drugs in cell and gene therapy.
The increase in outsourcing services by pharmaceutical companies in the pharmaceutical industry has profoundly impacted the Japan market.The trend of outsourcing activities in the pharmaceutical domain is rising as companies find value in acquiring additional competencies essential for successful drug development & commercialization. Besides providing extended expertise & assisting in improved cash flow management, outsourcing brings significant manufacturing advantages, including reducing investment risks.
Notably, regulatory authorities in Japan have accelerated approval for regenerative medical and gene therapy products. For instance, the adoption of the Pharmaceuticals and Medical Devices Act (PMD Act), 21st Century Cures Act, and PRIME (Priority Medicines) Initiative has helped the country improve access to regenerative medicines. Such initiatives by regulatory agencies are expected to improve the demand for the development and manufacturing of regenerative medicines in the country.
Japan CDMO Market Report Highlights
- The active pharmaceutical ingredient (API) segment dominated the market with a share of 81.2% in 2023. The segment growth is driven by competitive drug development and growing demand for end-to-end Contract Development & Manufacturing Organization (CDMO) services. In addition, advancements in API manufacturing, growth of the biopharmaceutical sector, and the increasing geriatric population are some of the key factors propelling segment growth
- Based on workflow, the commercial segment held the largest market share in 2023, attributed to robust demand for pharmaceutical products, such as biosimilar medications, generic medications, and regenerative therapies. This is where commercial CDMOs may help by providing knowledge, saving time, and being cost-effective.
- Based on application, the oncology segment dominated the test type market in 2023 with a revenue share of 35.3%, owing to the high cancer burden in the country. Approval of regenerative products and virotherapy for cancer treatment can further support market growth and the segment is further driven by increasing number of cancer cases globally. In addition, increasing pharmaceutical R&D investments, patent expirations, and demand for oncology drugs & biologic innovations are the factors driving the oncology segment growth
CHAPTER 1. METHODOLOGY AND SCOPE
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Product Type
1.2.2. Work Flow Type
1.2.3. Application
1.2.4. Estimates and forecasts timeline.
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR’s internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Product Type
2.2.2. Work Flow Type
2.2.3. Application
2.3. Competitive Insights
CHAPTER 3. JAPAN CDMO MARKET VARIABLES, TRENDS & SCOPE
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Growing demand for Biopharmaceutical drugs in Japan
3.2.1.2. High geriatric population and growing disease burden in Japan
3.2.1.3. Low cost associated with Outsourcing Drug Manufacturing and Development services
3.2.2. Market Restraint Analysis
3.2.2.1. Limited outsourcing opted by big pharma companies
3.2.2.2. Quality Issues While Outsourcing
3.3. Japan CDMO Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.2. PESTEL Analysis
CHAPTER 4. JAPAN CDMO MARKET: PRODUCT ESTIMATES & TREND ANALYSIS
4.1. Definitions and Scope
4.1.1. API
4.1.2. Drug Product
4.2. Product Market Share, 2023 & 2030
4.3. Segment Dashboard
4.4. Japan CDMO Market Movement Analysis
4.5. Japan CDMO Market Size & Trend Analysis, by Product, 2018 to 2030 (USD Million)
4.5.1. API
4.5.1.1. Market estimates and forecast 2018 to 2030 (USD Million)
4.5.1.2. Type
4.5.1.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
4.5.1.2.2. Traditional Active Pharmaceutical Ingredient (Traditional API)
4.5.1.2.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
4.5.1.2.3. Highly Potent Active Pharmaceutical Ingredient (HP-API)
4.5.1.2.3.1. Market estimates and forecast 2018 to 2030 (USD Million)
4.5.1.2.4. Antibody Drug Conjugate (ADC)
4.5.1.2.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
4.5.1.2.5. Others
4.5.1.2.5.1. Market estimates and forecast 2018 to 2030 (USD Million)
4.5.1.3. Synthesis
4.5.1.3.1. Market estimates and forecast 2018 to 2030 (USD Million)
4.5.1.3.2. Synthetic
4.5.1.3.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
4.5.1.3.2.2. Solid
4.5.1.3.2.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
4.5.1.3.2.3. Liquid
4.5.1.3.2.3.1. Market estimates and forecast 2018 to 2030 (USD Million)
4.5.1.3.3. Biotech
4.5.1.3.3.1. Market estimates and forecast 2018 to 2030 (USD Million)
4.5.1.4. Drug
4.5.1.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
4.5.1.4.2. Innovative
4.5.1.4.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
4.5.1.4.3. Generics
4.5.1.4.3.1. Market estimates and forecast 2018 to 2030 (USD Million)
4.5.1.5. Manufacturing
4.5.1.5.1. Continuous manufacturing
4.5.1.5.1.1. Market estimates and forecast 2018 to 2030 (USD Million)
4.5.1.5.2. Batch manufacturing
4.5.1.5.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
4.5.2. Drug Product
4.5.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
4.5.2.2. Oral solid dose
4.5.2.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
4.5.2.3. Semi-solid dose
4.5.2.3.1. Market estimates and forecast 2018 to 2030 (USD Million)
4.5.2.4. Liquid dose
4.5.2.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
4.5.2.5. Others
4.5.2.5.1. Market estimates and forecast 2018 to 2030 (USD Million)
CHAPTER 5. JAPAN CDMO MARKET: WORKFLOW ESTIMATES & TREND ANALYSIS
5.1. Definitions and Scope
5.1.1. Clinical
5.1.2. Commercial
5.2. Segment Dashboard
5.3. Japan CDMO Market Movement Analysis
5.4. Japan CDMO Market Size & Trend Analysis, by Workflow, 2018 to 2030 (USD Million)
5.4.1. Clinical
5.4.1.1. Market estimates and forecast 2018 to 2030 (USD Million)
5.4.2. Commercial
5.4.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
CHAPTER 6. JAPAN CDMO MARKET: APPLICATION ESTIMATES & TREND ANALYSIS
6.1. Definitions and Scope
6.1.1. Oncology
6.1.1.1. Small Molecule
6.1.1.2. Biologics
6.1.2. Infectious Diseases
6.1.3. Neurological Disorders
6.1.4. Cardiovascular Diseases
6.1.5. Metabolic Disorders
6.1.6. Autoimmune Diseases
6.1.7. Respiratory Diseases
6.1.8. Ophthalmology
6.1.9. Gastrointestinal Disorders
6.1.10. Hormonal Disorders
6.1.11. Hematological Disorders
6.1.12. Others
6.2. Segment Dashboard
6.3. Japan CDMO Market Movement Analysis
6.4. Japan CDMO Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
6.4.1. Oncology
6.4.1.1. Market Estimates and forecast 2018 to 2030 (USD million)
6.4.1.2. Small Molecule
6.4.1.2.1. Market estimates and forecast 2018 to 2030 (USD million)
6.4.1.3. Biologics
6.4.1.3.1. Market estimates and forecast 2018 to 2030 (USD million)
6.4.2. Infectious Diseases
6.4.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
6.4.3. Neurological Disorders
6.4.3.1. Market estimates and forecast 2018 to 2030 (USD Million)
6.4.4. Cardiovascular Diseases
6.4.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
6.4.5. Metabolic Disorders
6.4.5.1. Market estimates and forecast 2018 to 2030 (USD Million)
6.4.6. Autoimmune Diseases
6.4.6.1. Market estimates and forecast 2018 to 2030 (USD Million)
6.4.7. Respiratory Diseases
6.4.7.1. Market estimates and forecast 2018 to 2030 (USD Million)
6.4.8. Ophthalmology
6.4.8.1. Market estimates and forecast 2018 to 2030 (USD Million)
6.4.9. Gastrointestinal Disorders
6.4.9.1. Market estimates and forecast 2018 to 2030 (USD Million)
6.4.10. Hormonal Disorders
6.4.10.1. Market estimates and forecast 2018 to 2030 (USD Million)
6.4.11. Hematological Disorders
6.4.11.1. Market estimates and forecast 2018 to 2030 (USD Million)
6.4.12. Others
6.4.12.1. Market estimates and forecast 2018 to 2030 (USD Million)
CHAPTER 7. COMPETITIVE LANDSCAPE
7.1. Recent Developments & Impact Analysis, By Key Market Participants
7.2. Company/Competition Categorization
7.3. Vendor Landscape
7.4. Market Participant Categorization
7.4.1. List of key distributors and channel partners
7.4.2. Key customers
7.4.3. Key company market share analysis, 2023
7.4.4. Lonza
7.4.4.1. Company overview
7.4.4.2. Financial performance
7.4.4.3. Product benchmarking
7.4.4.4. Strategic initiatives
7.4.5. Thermo Fisher Scientific, Inc.
7.4.5.1. Company overview
7.4.5.2. Financial performance
7.4.5.3. Product benchmarking
7.4.5.4. Strategic initiatives
7.4.6. Recipharm AB
7.4.6.1. Company overview
7.4.6.2. Financial performance
7.4.6.3. Product benchmarking
7.4.6.4. Strategic initiatives
7.4.7. Laboratory Corporation of America Holdings (LabCorp)
7.4.7.1. Company overview
7.4.7.2. Financial performance
7.4.7.3. Product benchmarking
7.4.7.4. Strategic initiatives
7.4.8. Catalent, Inc.
7.4.8.1. Company overview
7.4.8.2. Financial performance
7.4.8.3. Product benchmarking
7.4.8.4. Strategic initiatives
7.4.9. WuXi AppTec, Inc.
7.4.9.1. Company overview
7.4.9.2. Financial performance
7.4.9.3. Product benchmarking
7.4.9.4. Strategic initiatives
7.4.10. Samsung Biologics
7.4.10.1. Company overview
7.4.10.2. Financial performance
7.4.10.3. Product benchmarking
7.4.10.4. Strategic initiatives
7.4.11. CordenPharma International
7.4.11.1. Company overview
7.4.11.2. Financial performance
7.4.11.3. Product benchmarking
7.4.11.4. Strategic initiatives
7.4.12. Cambrex Corporation
7.4.12.1. Company overview
7.4.12.2. Financial performance
7.4.12.3. Product benchmarking
7.4.12.4. Strategic initiatives
7.4.13. Bushu Pharmaceuticals Ltd.
7.4.13.1. Company overview
7.4.13.2. Financial performance
7.4.13.3. Product benchmarking
7.4.13.4. Strategic initiatives
7.4.14. CMIC HOLDINGS Co., LTD.
7.4.14.1. Company overview
7.4.14.2. Financial performance
7.4.14.3. Product benchmarking
7.4.14.4. Strategic initiatives
7.4.15. Nipro Corporation
7.4.15.1. Company overview
7.4.15.2. Financial performance
7.4.15.3. Product benchmarking
7.4.15.4. Strategic initiatives
7.4.16. Sumitomo Chemical Company, Limited
7.4.16.1. Company overview
7.4.16.2. Financial performance
7.4.16.3. Product benchmarking
7.4.16.4. Strategic initiatives
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Product Type
1.2.2. Work Flow Type
1.2.3. Application
1.2.4. Estimates and forecasts timeline.
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR’s internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Product Type
2.2.2. Work Flow Type
2.2.3. Application
2.3. Competitive Insights
CHAPTER 3. JAPAN CDMO MARKET VARIABLES, TRENDS & SCOPE
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Growing demand for Biopharmaceutical drugs in Japan
3.2.1.2. High geriatric population and growing disease burden in Japan
3.2.1.3. Low cost associated with Outsourcing Drug Manufacturing and Development services
3.2.2. Market Restraint Analysis
3.2.2.1. Limited outsourcing opted by big pharma companies
3.2.2.2. Quality Issues While Outsourcing
3.3. Japan CDMO Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.2. PESTEL Analysis
CHAPTER 4. JAPAN CDMO MARKET: PRODUCT ESTIMATES & TREND ANALYSIS
4.1. Definitions and Scope
4.1.1. API
4.1.2. Drug Product
4.2. Product Market Share, 2023 & 2030
4.3. Segment Dashboard
4.4. Japan CDMO Market Movement Analysis
4.5. Japan CDMO Market Size & Trend Analysis, by Product, 2018 to 2030 (USD Million)
4.5.1. API
4.5.1.1. Market estimates and forecast 2018 to 2030 (USD Million)
4.5.1.2. Type
4.5.1.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
4.5.1.2.2. Traditional Active Pharmaceutical Ingredient (Traditional API)
4.5.1.2.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
4.5.1.2.3. Highly Potent Active Pharmaceutical Ingredient (HP-API)
4.5.1.2.3.1. Market estimates and forecast 2018 to 2030 (USD Million)
4.5.1.2.4. Antibody Drug Conjugate (ADC)
4.5.1.2.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
4.5.1.2.5. Others
4.5.1.2.5.1. Market estimates and forecast 2018 to 2030 (USD Million)
4.5.1.3. Synthesis
4.5.1.3.1. Market estimates and forecast 2018 to 2030 (USD Million)
4.5.1.3.2. Synthetic
4.5.1.3.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
4.5.1.3.2.2. Solid
4.5.1.3.2.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
4.5.1.3.2.3. Liquid
4.5.1.3.2.3.1. Market estimates and forecast 2018 to 2030 (USD Million)
4.5.1.3.3. Biotech
4.5.1.3.3.1. Market estimates and forecast 2018 to 2030 (USD Million)
4.5.1.4. Drug
4.5.1.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
4.5.1.4.2. Innovative
4.5.1.4.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
4.5.1.4.3. Generics
4.5.1.4.3.1. Market estimates and forecast 2018 to 2030 (USD Million)
4.5.1.5. Manufacturing
4.5.1.5.1. Continuous manufacturing
4.5.1.5.1.1. Market estimates and forecast 2018 to 2030 (USD Million)
4.5.1.5.2. Batch manufacturing
4.5.1.5.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
4.5.2. Drug Product
4.5.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
4.5.2.2. Oral solid dose
4.5.2.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
4.5.2.3. Semi-solid dose
4.5.2.3.1. Market estimates and forecast 2018 to 2030 (USD Million)
4.5.2.4. Liquid dose
4.5.2.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
4.5.2.5. Others
4.5.2.5.1. Market estimates and forecast 2018 to 2030 (USD Million)
CHAPTER 5. JAPAN CDMO MARKET: WORKFLOW ESTIMATES & TREND ANALYSIS
5.1. Definitions and Scope
5.1.1. Clinical
5.1.2. Commercial
5.2. Segment Dashboard
5.3. Japan CDMO Market Movement Analysis
5.4. Japan CDMO Market Size & Trend Analysis, by Workflow, 2018 to 2030 (USD Million)
5.4.1. Clinical
5.4.1.1. Market estimates and forecast 2018 to 2030 (USD Million)
5.4.2. Commercial
5.4.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
CHAPTER 6. JAPAN CDMO MARKET: APPLICATION ESTIMATES & TREND ANALYSIS
6.1. Definitions and Scope
6.1.1. Oncology
6.1.1.1. Small Molecule
6.1.1.2. Biologics
6.1.2. Infectious Diseases
6.1.3. Neurological Disorders
6.1.4. Cardiovascular Diseases
6.1.5. Metabolic Disorders
6.1.6. Autoimmune Diseases
6.1.7. Respiratory Diseases
6.1.8. Ophthalmology
6.1.9. Gastrointestinal Disorders
6.1.10. Hormonal Disorders
6.1.11. Hematological Disorders
6.1.12. Others
6.2. Segment Dashboard
6.3. Japan CDMO Market Movement Analysis
6.4. Japan CDMO Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
6.4.1. Oncology
6.4.1.1. Market Estimates and forecast 2018 to 2030 (USD million)
6.4.1.2. Small Molecule
6.4.1.2.1. Market estimates and forecast 2018 to 2030 (USD million)
6.4.1.3. Biologics
6.4.1.3.1. Market estimates and forecast 2018 to 2030 (USD million)
6.4.2. Infectious Diseases
6.4.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
6.4.3. Neurological Disorders
6.4.3.1. Market estimates and forecast 2018 to 2030 (USD Million)
6.4.4. Cardiovascular Diseases
6.4.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
6.4.5. Metabolic Disorders
6.4.5.1. Market estimates and forecast 2018 to 2030 (USD Million)
6.4.6. Autoimmune Diseases
6.4.6.1. Market estimates and forecast 2018 to 2030 (USD Million)
6.4.7. Respiratory Diseases
6.4.7.1. Market estimates and forecast 2018 to 2030 (USD Million)
6.4.8. Ophthalmology
6.4.8.1. Market estimates and forecast 2018 to 2030 (USD Million)
6.4.9. Gastrointestinal Disorders
6.4.9.1. Market estimates and forecast 2018 to 2030 (USD Million)
6.4.10. Hormonal Disorders
6.4.10.1. Market estimates and forecast 2018 to 2030 (USD Million)
6.4.11. Hematological Disorders
6.4.11.1. Market estimates and forecast 2018 to 2030 (USD Million)
6.4.12. Others
6.4.12.1. Market estimates and forecast 2018 to 2030 (USD Million)
CHAPTER 7. COMPETITIVE LANDSCAPE
7.1. Recent Developments & Impact Analysis, By Key Market Participants
7.2. Company/Competition Categorization
7.3. Vendor Landscape
7.4. Market Participant Categorization
7.4.1. List of key distributors and channel partners
7.4.2. Key customers
7.4.3. Key company market share analysis, 2023
7.4.4. Lonza
7.4.4.1. Company overview
7.4.4.2. Financial performance
7.4.4.3. Product benchmarking
7.4.4.4. Strategic initiatives
7.4.5. Thermo Fisher Scientific, Inc.
7.4.5.1. Company overview
7.4.5.2. Financial performance
7.4.5.3. Product benchmarking
7.4.5.4. Strategic initiatives
7.4.6. Recipharm AB
7.4.6.1. Company overview
7.4.6.2. Financial performance
7.4.6.3. Product benchmarking
7.4.6.4. Strategic initiatives
7.4.7. Laboratory Corporation of America Holdings (LabCorp)
7.4.7.1. Company overview
7.4.7.2. Financial performance
7.4.7.3. Product benchmarking
7.4.7.4. Strategic initiatives
7.4.8. Catalent, Inc.
7.4.8.1. Company overview
7.4.8.2. Financial performance
7.4.8.3. Product benchmarking
7.4.8.4. Strategic initiatives
7.4.9. WuXi AppTec, Inc.
7.4.9.1. Company overview
7.4.9.2. Financial performance
7.4.9.3. Product benchmarking
7.4.9.4. Strategic initiatives
7.4.10. Samsung Biologics
7.4.10.1. Company overview
7.4.10.2. Financial performance
7.4.10.3. Product benchmarking
7.4.10.4. Strategic initiatives
7.4.11. CordenPharma International
7.4.11.1. Company overview
7.4.11.2. Financial performance
7.4.11.3. Product benchmarking
7.4.11.4. Strategic initiatives
7.4.12. Cambrex Corporation
7.4.12.1. Company overview
7.4.12.2. Financial performance
7.4.12.3. Product benchmarking
7.4.12.4. Strategic initiatives
7.4.13. Bushu Pharmaceuticals Ltd.
7.4.13.1. Company overview
7.4.13.2. Financial performance
7.4.13.3. Product benchmarking
7.4.13.4. Strategic initiatives
7.4.14. CMIC HOLDINGS Co., LTD.
7.4.14.1. Company overview
7.4.14.2. Financial performance
7.4.14.3. Product benchmarking
7.4.14.4. Strategic initiatives
7.4.15. Nipro Corporation
7.4.15.1. Company overview
7.4.15.2. Financial performance
7.4.15.3. Product benchmarking
7.4.15.4. Strategic initiatives
7.4.16. Sumitomo Chemical Company, Limited
7.4.16.1. Company overview
7.4.16.2. Financial performance
7.4.16.3. Product benchmarking
7.4.16.4. Strategic initiatives
LIST OF TABLES
Table 1 List of secondary sources
Table 2 List of Abbreviations
Table 3 Japan CDMO Market, By Product Type, 2018 - 2030 (USD Million)
Table 4 Japan CDMO Market, Work Flow Type, 2018 - 2030 (USD Million)
Table 5 Japan CDMO Market, By Application, 2018 - 2030 (USD Million)
Table 6 ADC Approvals in Japan
Table 7 Financial performance
Table 8 Key company initiating service launches/upgrades
Table 9 Key companies initiating service launches/upgrades
Table 10 Key companies initiating partnerships
Table 11 Key companies initiating expansion
Table 12 Key companies initiating expansion
Table 1 List of secondary sources
Table 2 List of Abbreviations
Table 3 Japan CDMO Market, By Product Type, 2018 - 2030 (USD Million)
Table 4 Japan CDMO Market, Work Flow Type, 2018 - 2030 (USD Million)
Table 5 Japan CDMO Market, By Application, 2018 - 2030 (USD Million)
Table 6 ADC Approvals in Japan
Table 7 Financial performance
Table 8 Key company initiating service launches/upgrades
Table 9 Key companies initiating service launches/upgrades
Table 10 Key companies initiating partnerships
Table 11 Key companies initiating expansion
Table 12 Key companies initiating expansion
LIST OF FIGURES
Fig. 1 Market research process
Fig. 2 Information procurement
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 QFD modeling for market share assessment
Fig. 6 Market formulation & validation
Fig. 7 Commodity flow analysis
Fig. 8 Volume price analysis
Fig. 9 Japan CDMO market snapshot, 2023 (in USD Million)
Fig. 10 Segment snapshot, 2023 & 2030 (USD Million)
Fig. 11 Workflow Segment snapshot, 2023 & 2030 (USD Million)
Fig. 12 Competitive landscape snapshot
Fig. 13 Market dynamics
Fig. 14 Risk associated with outsourcing services
Fig. 15 Porter’s five forces analysis
Fig. 16 PESTEL Analysis
Fig. 17 Japan CDMO market Product outlook: Segment dashboard
Fig. 18 Japan CDMO market: Product movement analysis
Fig. 19 API market, 2018 - 2030 (USD Million)
Fig. 20 Traditional APIs market, 2018 - 2030 (USD Million)
Fig. 21 HP-API market, 2018 - 2030 (USD Million)
Fig. 22 Antibody drug conjugate market, 2018 - 2030 (USD Million)
Fig. 23 Others market, 2018 - 2030 (USD Million)
Fig. 24 Synthetic market, 2018 - 2030 (USD Million)
Fig. 25 Solid market, 2018 - 2030 (USD Million)
Fig. 26 Liquid market, 2018 - 2030 (USD Million)
Fig. 27 No. of Biosimilar approvals (2012-2021)
Fig. 28 Biotech market, 2018 - 2030 (USD Million)
Fig. 29 Innovative market, 2018 - 2030 (USD Million)
Fig. 30 Generics market, 2018 - 2030 (USD Million)
Fig. 31 Continuous manufacturing process of tablets
Fig. 32 Continuous manufacturing market, 2018 - 2030 (USD Million)
Fig. 33 Batch manufacturing process
Fig. 34 Batch manufacturing market, 2018 - 2030 (USD Million)
Fig. 35 Oral solid dose market, 2018 - 2030 (USD Million)
Fig. 36 Semi-solid dose market, 2018 - 2030 (USD Million)
Fig. 37 Liquid dose market, 2018 - 2030 (USD Million)
Fig. 38 Others market, 2018 - 2030 (USD Million)
Fig. 39 Japan CDMO market workflow outlook: Segment dashboard
Fig. 40 Japan CDMO market: Workflow movement analysis
Fig. 41 Japan clinical trial
Fig. 42 Clinical market, 2018 - 2030 (USD Million)
Fig. 43 Commercial market, 2018 - 2030 (USD Million)
Fig. 44 Japan CDMO market synthesis outlook: segment dashboard
Fig. 45 Japan CDMO market: synthesis movement analysis
Fig. 46 Oncology market, 2018 - 2030 (USD Million)
Fig. 47 Hormonal market, 2018 - 2030 (USD Million)
Fig. 48 Glaucoma market, 2018 - 2030 (USD Million)
Fig. 49 Cardiovascular disease market, 2018 - 2030 (USD Million)
Fig. 50 Diabetes market, 2018 - 2030 (USD Million)
Fig. 51 Others market, 2018 - 2030 (USD Million)
Fig. 52 Market participant categorization
Fig. 53 Heat map analysis
Fig. 54 Market participant categorization
Fig. 1 Market research process
Fig. 2 Information procurement
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 QFD modeling for market share assessment
Fig. 6 Market formulation & validation
Fig. 7 Commodity flow analysis
Fig. 8 Volume price analysis
Fig. 9 Japan CDMO market snapshot, 2023 (in USD Million)
Fig. 10 Segment snapshot, 2023 & 2030 (USD Million)
Fig. 11 Workflow Segment snapshot, 2023 & 2030 (USD Million)
Fig. 12 Competitive landscape snapshot
Fig. 13 Market dynamics
Fig. 14 Risk associated with outsourcing services
Fig. 15 Porter’s five forces analysis
Fig. 16 PESTEL Analysis
Fig. 17 Japan CDMO market Product outlook: Segment dashboard
Fig. 18 Japan CDMO market: Product movement analysis
Fig. 19 API market, 2018 - 2030 (USD Million)
Fig. 20 Traditional APIs market, 2018 - 2030 (USD Million)
Fig. 21 HP-API market, 2018 - 2030 (USD Million)
Fig. 22 Antibody drug conjugate market, 2018 - 2030 (USD Million)
Fig. 23 Others market, 2018 - 2030 (USD Million)
Fig. 24 Synthetic market, 2018 - 2030 (USD Million)
Fig. 25 Solid market, 2018 - 2030 (USD Million)
Fig. 26 Liquid market, 2018 - 2030 (USD Million)
Fig. 27 No. of Biosimilar approvals (2012-2021)
Fig. 28 Biotech market, 2018 - 2030 (USD Million)
Fig. 29 Innovative market, 2018 - 2030 (USD Million)
Fig. 30 Generics market, 2018 - 2030 (USD Million)
Fig. 31 Continuous manufacturing process of tablets
Fig. 32 Continuous manufacturing market, 2018 - 2030 (USD Million)
Fig. 33 Batch manufacturing process
Fig. 34 Batch manufacturing market, 2018 - 2030 (USD Million)
Fig. 35 Oral solid dose market, 2018 - 2030 (USD Million)
Fig. 36 Semi-solid dose market, 2018 - 2030 (USD Million)
Fig. 37 Liquid dose market, 2018 - 2030 (USD Million)
Fig. 38 Others market, 2018 - 2030 (USD Million)
Fig. 39 Japan CDMO market workflow outlook: Segment dashboard
Fig. 40 Japan CDMO market: Workflow movement analysis
Fig. 41 Japan clinical trial
Fig. 42 Clinical market, 2018 - 2030 (USD Million)
Fig. 43 Commercial market, 2018 - 2030 (USD Million)
Fig. 44 Japan CDMO market synthesis outlook: segment dashboard
Fig. 45 Japan CDMO market: synthesis movement analysis
Fig. 46 Oncology market, 2018 - 2030 (USD Million)
Fig. 47 Hormonal market, 2018 - 2030 (USD Million)
Fig. 48 Glaucoma market, 2018 - 2030 (USD Million)
Fig. 49 Cardiovascular disease market, 2018 - 2030 (USD Million)
Fig. 50 Diabetes market, 2018 - 2030 (USD Million)
Fig. 51 Others market, 2018 - 2030 (USD Million)
Fig. 52 Market participant categorization
Fig. 53 Heat map analysis
Fig. 54 Market participant categorization
